Yeah, no, and thanks for asking those. I think the first question was around the commercial infrastructure build-out in the near term. And certainly, you know, concur with the team. I've been on the board, so I've been a part of a lot of these discussions. You know, the first thing I would say is, you know, we have a great partner in V4. that they are taking, they're doing the full commercialization with Corsuva injection. So we're pretty excited about that and partnering with them. And, you know, I think that's some of the value I could bring working on the launch with not only our team at CARA, who we've got a great commercial lead, and then also working, obviously, with V4. So we'll be really focused on ensuring a successful launch of the Corsuva injection I think longer term, you know, as we think about commercial infrastructure buildup, that's something that we'll look as we progress the data.

Nov 8, 2021 / receipt, needs a key / Chris, CEO | earnings call 2021-11-08 | transcript e41dec29-ad87-4e32-9f10-557cbe70e13c | chars 25502-26413 | segment 25

The lower R&D expenses in 2020 were principally due to a net decrease in costs associated with clinical trials and travel costs, partially offset by a $2.5 million milestone payment made in connection with a license agreement within tariffs, increase in payroll and related costs, and increases in stock compensation expense.

Feb 25, 2021 / receipt, needs a key / Thomas Riley, CFO | earnings call 2021-02-25 | transcript ebf3fe3e-cdf5-4ad4-b55e-3bf7ee440a31 | chars 11586-11911 | segment 11

The lower R&D expenses in 2020 were principally due to a net decrease in clinical trial costs, lower payments made to interest, and a decrease in travel costs, partially offset by increases in stock compensation expense, payroll and related costs, and cost of clinical compound sales.

Feb 25, 2021 / receipt, needs a key / CFO, CFO | earnings call 2021-02-25 | transcript ebf3fe3e-cdf5-4ad4-b55e-3bf7ee440a31 | chars 13476-13760 | segment 13